



1 May 2018

Company Announcements Office

**ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000**

Dear Sir / Madam,

Notification under sections 708A(5)(e) of the Corporations Act 2001 (Cth)

AtCor has today issued an Appendix 3B with respect to the placement of 41,500,000 ordinary shares announced on 23 April 2018 (**Placement**). Details of the Placement are set out in the announcement of 23 April 2017 and in today's Appendix 3B.

AtCor gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

1. Under the Placement, AtCor has issued 41,500,000 ordinary shares at the issue price of \$0.02 per share, raising approximately \$830,000 without disclosure to investors under Part 6D.2 of the Corporations Act.
2. As at the date of this notice:
 - (a) AtCor has complied with the provisions of Chapter 2M of the Act;
 - (b) AtCor has complied with section 674 of the Act; and
 - (c) there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act.

Yours faithfully,

A handwritten signature in blue ink, appearing to read 'Jarrod White', is written over a faint blue line.

Jarrod White
Company Secretary | Chief Financial Officer

About AtCor Medical

AtCor Medical develops and markets products for large-scale population health disorders with a focus on cardiovascular disease.

*For further information, please contact
(AtCor):*

Jarrod White
Company Secretary
+61 (2) 8815 8811
j.white@atcormedical.com

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Phone: +61 (2) 8264 1004
Mobile: +61 407 231 282
a.rambukwella@fcr.com.au

For personal use only